These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29945753)

  • 1. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
    Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
    Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
    [No Abstract]   [Full Text] [Related]  

  • 2. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Alexander M; Pavlakis N; John T; O'Connell R; Kao S; Hughes BGM; Lee A; Hayes SA; Howell VM; Clarke SJ; Millward M; Burbury K; Solomon B; Itchins M
    Lung Cancer; 2020 Apr; 142():34-40. PubMed ID: 32087434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.
    Solomon B
    J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features.
    Zhou J; Zhao J; Zheng J; Kong M; Sun K; Wang B; Chen X; Ding W; Zhou J
    PLoS One; 2016; 11(9):e0161861. PubMed ID: 27648828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
    Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
    J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.
    Shah AT; Bernardo RJ; Berry GJ; Kudelko K; Wakelee HA
    Clin Lung Cancer; 2021 Mar; 22(2):e153-e156. PubMed ID: 33153897
    [No Abstract]   [Full Text] [Related]  

  • 12. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent thrombosis followed by Lazarus response in
    Beninato T; Lo Russo G; Garassino MC; De Braud F; Platania M
    Tumori; 2020 Dec; 106(6):NP41-NP45. PubMed ID: 32066344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.
    Zeng L; Yang N; Zhang Y
    J Thorac Oncol; 2018 Jul; 13(7):e114-e116. PubMed ID: 29935846
    [No Abstract]   [Full Text] [Related]  

  • 18. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
    Lambros L; Guibourg B; Uguen A
    Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
    [No Abstract]   [Full Text] [Related]  

  • 19. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
    Riess JW; Padda SK; Bangs CD; Das M; Neal JW; Adrouny AR; Cherry A; Wakelee HA
    Clin Lung Cancer; 2013 Sep; 14(5):592-5. PubMed ID: 23810364
    [No Abstract]   [Full Text] [Related]  

  • 20. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.